Pharming Group N.V.

Regulatory Filings • Sep 20, 2007

PHARMING TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE

Leiden, The Netherlands, September 19, 2007. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) today announced that Pharming will present at the UBS Global Life Sciences (September 24-27, 2007) in New York.

Dr. Francis Pinto, Chief Executive Officer of Pharming, will present on Wednesday, September 26 at 2:00 pm Eastern Time. The presentation will be available on Pharming's website after the meeting. The conference attendees include institutional investors from the United States, Europe and Asia-Pacific. For further information on the UBS Global Life Sciences Conference, please visit www.ibb.ubs.com.

Background on Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker Julia Philips Rein Strijker Investor Voice Financial Dynamics Pharming Group NV T: +31 (0)6 537 499 59 T: +44 (0)20 7269 7148 T: +31 (0)71 52 47 400 T: +31 (0)71 52 47 400 T: +44 (0)7747 602 739